FGFR1 expression	Ovarian Cancer	FGFR1 expression	Ovarian Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
FGFR1 expression	Urothelial Cancer	FGFR1 expression	Urothelial Cancer	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2
FGFR1 expression	Urothelial Cancer	FGFR1 expression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3
FGFR1 expression	Squamous Cell Carcinoma of Head and Neck	FGFR1 expression	Squamous Cell Carcinoma of Head and Neck	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR1 expression	Breast Cancer	FGFR1 expression	Breast Cancer	ARQ 087 Sensitive: D – Preclinical ARQ 087 Sensitive : D	ARQ 087 Sensitive: D – Preclinical ARQ 087 Sensitive : D

FGFR1 expression

Associations